0001193125-23-004274.txt : 20230109 0001193125-23-004274.hdr.sgml : 20230109 20230109092603 ACCESSION NUMBER: 0001193125-23-004274 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 23516882 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 d446015d8k.htm 8-K 8-K
NY false 0001802768 0001802768 2023-01-09 2023-01-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2023

 

 

Royalty Pharma plc

(Exact Name of Registrant as Specified in its Charter)

 

 

 

England and Wales   001-39329   98-1535773

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

110 East 59th Street

New York , New York

   10022
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (212) 883-0200

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Class A Ordinary Shares, par value $0.0001 per share   RPRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On January 9, 2023, Royalty Pharma plc issued a press release providing a preliminary update on the year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit

No.

    Description
99.1    Press release issued by Royalty Pharma plc, dated January 9, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    ROYALTY PHARMA PLC
Date: January 9, 2023     By:  

/s/ Terrance Coyne

      Terrance Coyne
      Chief Financial Officer
 EX-99.1 2 d446015dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    PRESS RELEASE

ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

 

  •  

2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be approximately $2,785 million to $2,790 million, towards the upper end of guidance range

 

  •  

Announced transactions of $10 billion since 2020 expected to add ~$1 billion to Adjusted Cash Receipts(1) (non-GAAP) in 2025

NEW YORK, NY, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments and the full year 2022 outlook for Net cash provided by operating activities (GAAP financial measure) and Adjusted Cash Receipts(1) (non-GAAP financial measure). Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer, will discuss these updates today as part of a webcast presentation at the 41st Annual J.P. Morgan Healthcare Conference to be held at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time.

“Royalty Pharma delivered outstanding performance in 2022,” said Pablo Legorreta. “We deployed substantial capital and added royalties on six new therapies, ranging from an approved, growing blockbuster to exciting development-stage therapies in areas of high unmet patient need. Further, we hosted our inaugural Investor Day, highlighting our talented team, the unique strength of our business model, and our strategy to drive long-term, compounding growth. Lastly, we expect to achieve the upper end of our 2022 financial guidance, putting us in a strong position to accelerate innovation in life sciences and transform patient lives globally.”

Strong 2022 Financial Performance

Based on preliminary unaudited fourth quarter 2022 results, Royalty Pharma expects Net cash provided by operating activities (GAAP) to be approximately $2,140 million to $2,150 million for full year 2022. Additionally, Royalty Pharma now expects to deliver Adjusted Cash Receipts(1) (non-GAAP) for full year 2022 of approximately $2,785 million to $2,790 million, which is towards the upper end of its guidance range of $2,750 million to $2,800 million and represents growth of 31% year-over-year. This strong double-digit growth in Adjusted Cash Receipts reflects the strong performance of Royalty Pharma’s diversified royalty portfolio as well as the acceleration of payments related to Pfizer’s acquisition of Biohaven. Importantly, the growth in Adjusted Cash Receipts was achieved despite a significant decline in two of Royalty Pharma’s largest royalties in previous years, the HIV and DPP-IV franchises, highlighting the resilience of the business model with a unique ability to grow through royalty expirations.

Royalty Pharma’s preliminary unaudited fourth quarter 2022 results provided in this press release are subject to change in connection with the completion of the company’s final closing procedures, final adjustments and other developments that may arise in the course of the preparation or audit of its financial statements. Royalty Pharma’s management will host a conference call to discuss Royalty Pharma’s fourth quarter and full year 2022 results in February.

 

 

LOGO

LOGO    PRESS RELEASE

 

Strong Capital Deployment Added Innovative Therapies, Enhancing Long-term Growth

Since 2020, Royalty Pharma has announced transactions of $10 billion, including $3.4 billion in 2022. Important additions to Royalty Pharma’s portfolio in the past year have included the growing respiratory therapy, Trelegy, as well as the potentially practice-changing, development-stage compounds, olpasiran and aficamten (both for cardiovascular disease) and MK-8189 (schizophrenia). In total, 29 unique therapies have been added to the company’s portfolio since 2020 (of which 14 are either currently or projected to be blockbusters that generate annual sales of $1 billion or more based on consensus estimates). These new medicines are expected to make a significant contribution to Royalty Pharma’s financial performance in the coming years. In aggregate, based on consensus sales forecasts, investments made since 2020 are estimated to add approximately $1 billion to Royalty Pharma’s annual Adjusted Cash Receipts(1) (non-GAAP) in 2025.

Biotech Funding Environment Driving New Royalty Opportunities

The biopharmaceutical ecosystem is generating significant demands for capital to fund the ongoing wave of healthcare innovation. Reflecting this positive market backdrop, between 2019 and 2022, the number of initial and in-depth reviews of new royalty opportunities conducted by Royalty Pharma increased by 75%, resulting in a 55% increase in announced annual transaction value (from $2.2 billion in 2019 to $3.4 billion in 2022). Looking ahead, Royalty Pharma estimates that the biopharma ecosystem will cumulatively spend more than $4 trillion to fund life sciences research and development over the next decade (of which unprofitable biopoharma will spend more than $1 trillion including SG&A), which is expected to generate many new royalty opportunities.

Given Royalty Pharma’s unique role at the heart of funding life sciences innovation, Royalty Pharma believes that there will be significant opportunity to deploy capital and fund innovation, while creating value for its stakeholders. This is reflected in the company’s capital deployment target of $10 billion to $12 billion over the next five years and in Royalty Pharma’s expectation that it has the potential over the longer term to double its average annual capital deployment to $4 billion to $5 billion.

Webcast of J.P. Morgan Healthcare Conference

Royalty Pharma will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. ET / 8:15 a.m. PT today. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly—directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates.

 

LOGO

LOGO    PRESS RELEASE

 

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

 

LOGO

LOGO    PRESS RELEASE

 

Use of Non-GAAP Measures

Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to Royalty Pharma’s GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because operating performance is a function of liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures Royalty Pharma uses in the same manner. Royalty Pharma compensates for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being net cash provided by operating activities. Royalty Pharma believes that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about its operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising its operating results. Management strongly believes that Royalty Pharma’s significant operating cash flow is one of the attributes that attracts potential investors to its business.

In addition, Royalty Pharma believes that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Both measures are an indication of the strength of the company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities. Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing liquidity and is a key component of certain material covenants contained within the company’s Credit Agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of Royalty Pharma’s liquidity.

Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the company’s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. Royalty Pharma believes that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in Royalty Pharma’s industry.

 

LOGO

LOGO    PRESS RELEASE

 

The non-GAAP financial measures used in this press release have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP. The company has provided a reconciliation of Adjusted Cash Receipts as used in this press release at Table 1.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772

ir@royaltypharma.com

Table 1 – GAAP to Non-GAAP Reconciliation (unaudited)

 

($ in millions)    Full-year 2022

Net cash provided by operating activities (GAAP)

    $2,140 - 2,150

Adjustments:

   

Proceeds from available for sale debt securities(2)(3)

    540 - 545

Interest paid, net(2)

    144 - 145

Development-stage funding payments - ongoing

    2 - 3

Development-stage funding payments - upfront and milestone

    170 - 175

Payments for operating and professional costs

    220 - 225

Distributions to non-controlling interests(2)

    (435 - 445)

Adjusted Cash Receipts(1) (non-GAAP)

    $2,785 - 2,790  
Amounts may not add due to ranges presented by line item.   

Notes

 

(1)

Adjusted Cash Receipts is a measure calculated with inputs directly from the statement of cash flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from equity method investees, plus (2) Proceeds from available for sale debt securities; less (3) Distributions to non-controlling interests, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to the Company’s historical non-controlling interests related to the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust (RPSFT). See Royalty Pharma’s Annual Report on Form 10-K filed with the SEC on February 15, 2022 for additional discussion.

(2)

The table below shows the line item for each adjustment and the direct location for such line item on the statement of cash flows.

 

Reconciling Adjustment

   

Statement of Cash Flows Classification

Proceeds from available for sale debt securities    Investing activities
Distributions to non-controlling interests    Financing activities
Interest paid, net    Operating activities (Interest paid less Interest received)

 

3)

Receipts from the redemption of Royalty Pharma’s Series A and Series B Biohaven Preferred Shares are presented as Proceeds from available for sale debt securities on the statement of cash flows.

 

LOGO

EX-101.SCH 3 rprx-20230109.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rprx-20230109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rprx-20230109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g446015dsp7a.jpg GRAPHIC begin 644 g446015dsp7a.jpg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g446015dsp7b.jpg GRAPHIC begin 644 g446015dsp7b.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 09, 2023
Cover [Abstract]  
Entity Address, State or Province NY
Amendment Flag false
Entity Central Index Key 0001802768
Document Type 8-K
Document Period End Date Jan. 09, 2023
Entity Registrant Name Royalty Pharma plc
Entity Incorporation State Country Code X0
Entity File Number 001-39329
Entity Tax Identification Number 98-1535773
Entity Address, Address Line One 110 East 59th Street
Entity Address, City or Town New York
Entity Address, Postal Zip Code 10022
City Area Code (212)
Local Phone Number 883-0200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol RPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d446015d8k_htm.xml IDEA: XBRL DOCUMENT 0001802768 2023-01-09 2023-01-09 NY false 0001802768 8-K 2023-01-09 Royalty Pharma plc X0 001-39329 98-1535773 110 East 59th Street New York 10022 (212) 883-0200 false false false false Class A Ordinary Shares, par value $0.0001 per share RPRX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $%+*58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !!2RE6#Y9J#.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y&82;-I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,1@M(? MZHA0<;X"AZ2,(@4SL @+D;6-T5)'5-3'"][H!1\^8Y=A1@-VZ-!3 E$*8.T\ M,9S'KH$;8(811I>^"V@68J[^B\GK%M8G M4E[C]"M92>> :W:=_%IO'O=;UE:\J@LN"OZP%_>R6DDNWF?7'WXW8=<;>[#_ MV/@JV#;PZR[:+U!+ P04 " !!2RE6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $%+*58-4EGV700 * 0 8 >&PO=V]R:W-H965T&UL ME9AA<^(V$(;_BL:]Z;0SE]@R(4 *S!"2M.G=)132WET[_2!L 9JS)5>20_CW MM[*)37MF3;\$R_:^?B3MOI(RW"K]Q6PXM^0E3:09>1MKLRO?-]&&I\R+)2.F46FGKMFTQS%A=!:>*'07#IITQ(;SPL[LWT>*ARFPC)9YJ8/$V9WEWS M1&U''O5>;\S%>F/=#7\\S-B:+[C]/9MI:/F52BQ2+HU0DFB^&GD3>G4=7KB MXHT_!-^:@VOBNK)4ZHMKW,)4P*.?_:B7O5-%WAX M_:I^5W0>.K-DAD]5\E'$=C/R^AZ)^8KEB9VK[2]\WZ&NTXM48HJ_9%N^>Q%X M),J-5>D^& A2(QO4W$71 MU2(:X(1TL[*P&IX*B+/C&Q7E,,B6,!F36VF%W9%[6X#VP58%@!AH5>YXC>5#US3?Z:+(W5,(5_-Q&5 M"A?-"BZOKTS&(C[R('$-U\_<&W__';T,?D+X.A5?!U,?[\=L$L>@;=Z2A666 M$Z7)3*MG(2/>!(Q+/GQ&N"XJK@M49 *S&AY>P=1,$'K]BB>$(1[?BZ)XR M/E,@T2R!W(KY"WG'=TU$N%(0!+0?A+W+/H)U66%=HF)5WC_MLL8IPL/[9^\0 MB%X%T3L-8L:U4*[^8@)5W,B#*Q555Y1=6]WU*[;^*?,VYVOA*@\@'UC:2(;K MS-6.)2 TVS#P%)(E$0(WJ. &I\#=RTCI3.G"JO:5-U4Y9!HDG(H;:7'A3P%" M1X/:5(-3^.Y$PLE#GBZY;C127 32_:PSZ(0##.G Y^DI2$_LA=S'D'-B):)R MW!! 7'+0/Z/=3K?7P_*-UD9/49_^QDGW%^0]O$<>9>-LMDA2&I!;9BSI#NP& M$D3#,HFQUJ9/_Y_K3UT+3/]);9O7S!;'A]W+9]B]8&RU\5/C&@N(<7XS2![>-Q%%S@AY"&/V(H]0) <0M_KR(8E=E& M2;1&6]:!?N:5X,#X>-5;E\PRX']H>/J]61^R-L 6V5; >@$(<;=>\"C7KOQHN"1/PB:-Y=7>>4(>=2PD'.7( M9V#DZ3,4V>69)S\B8X=]LUDD'7C7N*=>'@*(#;^9-F ML4O%Q2Y=JL9$;!&8S^:?,)+:_T/6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK M6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9) ML;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2 MVSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK= M5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>6 M5Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEU MXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z M6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$// M\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?# M$T%^@2O&+(=/EB>N$_N MG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"= MXI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C% M^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_ M5U/\!%!+ P04 " !!2RE6EXJ[', 3 @ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N M&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E MC'%BM/XU@LD/['X 4$L#!!0 ( $%+*58<.&7J/P$ #P" / >&PO M=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O M RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD M#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A M'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT M^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179E MH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748 MJ&2WEYIK=WDWM) MJ'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/ M3K3G>1,)KM\,<'AT_@%02P,$% @ 04LI5F60>9(9 0 SP, M !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V + M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5 M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:> M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/] M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 M" !!2RE6!T%-8H$ "Q $ @ $ 9&]C4')O<',O M87!P+GAM;%!+ 0(4 Q0 ( $%+*58/EFH,[@ "L" 1 M " :\ !D;V-0&UL M4$L! A0#% @ 04LI5@U26?9=! H! !@ ("!#0@ M 'AL+W=O7!E&UL4$L%!@ ) D /@( 4 ! $! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince - d446015d8k.htm 7 d446015d8k.htm d446015dex991.htm rprx-20230109.xsd rprx-20230109_lab.xml rprx-20230109_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d446015d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d446015d8k.htm" ] }, "labelLink": { "local": [ "rprx-20230109_lab.xml" ] }, "presentationLink": { "local": [ "rprx-20230109_pre.xml" ] }, "schema": { "local": [ "rprx-20230109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20230109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d446015d8k.htm", "contextRef": "duration_2023-01-09_to_2023-01-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d446015d8k.htm", "contextRef": "duration_2023-01-09_to_2023-01-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com//20230109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001193125-23-004274-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-004274-xbrl.zip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